HSC01
clear graphic
clear graphic

CTRC researchers: More Hispanics needed for cancer trials

Posted: Friday, May 30, 2014 · Volume: XLVII · Issue: 11

Share |


Anand Karnad, M.D., chief of the Division of Hematology/Oncology at the Cancer Therapy & Research Center, urges physicians and researchers to increase the number of Hispanics in cancer clinical trials.
clear graphic
Anand Karnad, M.D., chief of the Division of Hematology/Oncology at the Cancer Therapy & Research Center, urges physicians and researchers to increase the number of Hispanics in cancer clinical trials.clear graphic

Email Printer Friendly Format
 

Contact: Elizabeth Allen, 210-450-2020

SAN ANTONIO (May 19, 2014) — Hispanics are the fastest-growing demographic group in the United States. They suffer from major health disparities, including higher rates of cervical, stomach and liver cancer. However, their enrollment in cancer clinical trials seeking to cure these problems is abysmally low: 3.9 percent.

In a paper published May 19 in the “Comments and Controversies” section of the Journal of Clinical Oncology, three physicians from the UT Health Science Center San Antonio are issuing a call to arms to other cancer researchers to improve their recruitment of Hispanic patients into clinical trials.

Low participation
“Fundamentally, in the most recent published cancer clinical trials, either the number and proportion of Hispanics are not reported or are far below their actual representation in the national population,” said Ian M. Thompson Jr., M.D., director of the Health Science Center’s Cancer Therapy & Research Center.

“We have a major responsibility to ensure adequate representation,” Dr. Thompson said. “How else will we know how best to treat our patients, and how else are we going to reduce the health disparities in this population?”

CTRC researchers study region’s Hispanic participation
Dr. Thompson, Anand Karnad, M.D., chief of the Division of Hematology/Oncology at the CTRC, and Alberto Parra, M.D., internal medicine resident at the UT Health Science Center, examined clinical trial participation.
The researchers, including internal medicine resident Alberto Parra, M.D.,  found Hispanics compose only 3.9 percent of cancer clinical trial participants nationally. In 2012, however, 45 percent of patients in CTRC clinical trials were Hispanic due to efforts to remove barriers to participation.
clear graphic
The researchers, including internal medicine resident Alberto Parra, M.D., found Hispanics compose only 3.9 percent of cancer clinical trial participants nationally. In 2012, however, 45 percent of patients in CTRC clinical trials were Hispanic due to efforts to remove barriers to participation.clear graphic

 

Fifty-eight percent of San Antonio residents are Hispanic, with 68 percent in the South Texas region as a whole. As the National Cancer Institute-designated cancer center serving South Texas, the CTRC has a strategic focus on improving health care in the region by working to increase Hispanic participation in cancer clinical trials.

Addressing the barriers
In 2012, 45 percent of the 822 patients enrolled onto the clinical trials offered at CTRC were Hispanic. The CTRC achieved this by studying ways to reduce barriers that might be unique to Hispanic patients. The CTRC also developed a minority recruitment toolbox with bilingual forms and created a coordinator of minority programs who is bilingual.

“For institutions like ours that serve a ‘minority-majority’ population, it’s a major responsibility for us to ensure adequate representation so that we can tell our patients how they can best be treated and how we can reduce the disparities of this rapidly-growing population,” Dr. Thompson said.

###

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI)-designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net.

 
bottom bar

»printer friendly format...
»view more articles by issue#...
»search articles by keywords...
Arrow - to top
HSC Alert - Sign up today
Calendar of Events
Tell Us Your Story Idea
Submission Guidelines
Arrow - to top